Precision Biosciences DTIL
- Market cap
- $191.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $45M
- growth n/m, growth from a base too small to compare
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −27.1%
Precision Biosciences trades at 4.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $45M over the last twelve months.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7M−34% | $17.6M+100% | $49.9M+152% | $576K−96% | $638K−91% | $29K−100% | $18K−100% | $13K−98% | $34.2M+5261% | $10.8M+37272% | $0 | $0 | |
| R&D | $13.4M−37% | $13.3M+21% | $17.2M+32% | $13.1M−18% | $15.9M+19% | $13.6M+2% | $12.8M−26% | $13.4M+2% | $14.5M−9% | $13.1M−4% | $12.4M−3% | $12.7M−5% |
| SG&A | $8.5M−15% | $8.4M−24% | $8.5M−13% | $8.8M−9% | $9.6M+12% | $8.6M+2% | $9.1M+7% | $7.3M−16% | $7.2M−25% | $6.8M−21% | $6.8M−26% | $7.7M+5% |
| −$14.9M−27% | −$4.2M−69% | $24.1M | −$21.3M+72% | −$24.8M+67% | −$22.1M+428% | −$21.9M | −$20.7M−3% | $12.5M | −$9.1M−59% | −$19.2M−12% | −$20.4M−1% | |
| Interest expense | $579K+19% | $574K+10% | $560K+1% | $256K−56% | $392K−32% | $354K−38% | $358K−36% | $362K+41% | $348K−11% | $311K−12% | $300K−16% | $307K−15% |
| Net income | −$16.3M−43% | $8.6M | $32.7M | −$16.4M+103% | −$17.7M+9% | −$20.6M | −$23.5M | −$21.8M+33% | $20.1M | −$18.4M−10% | −$32.7M+39% | −$7.6M−65% |
| −$4.06−48% | $1.70 | $4.67 | −$2.25+7% | −$2.22−45% | −$2.21 | −$2.13 | −$1.84−18% | $1.06 | −$0.75−66% | −$1.26−41% | −$0.28−85% | |
| 4M+8% | 5.1M+37% | 7M+84% | 7.3M+90% | 8M+100% | 9.3M+84% | 11M+58% | 11.8M+62% | 19.1M+138% | 24.6M+165% | 25.9M+134% | 27.4M+132% |
EPS, diluted: 8 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Precision Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DTILPrecision Biosciences | $191.8M | n/m | 78.9× | 4.3× | n/m | n/m | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $223.9M | 20.4× | 29.0× | 3.0× | +15% | 15.3% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| CYHCommunity Health Systems | $296.2M | 8.1× | 4.5× | 0.0× | −8% | 0.3% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| VMDViemed Healthcare | $359.6M | 26.2× | 26.2× | 1.2× | +25% | 4.8% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| Peer median | $224.2M | 14.0× | 20.5× | 1.6× | +6% | 7.3% |
More on Precision Biosciences
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .